双环氮杂环丁烷通过抑制寄生虫苯丙氨酰-tRNA合成酶杀死小鼠体内的腹泻病原体隐孢子虫
隐孢子虫是幼儿腹泻病和死亡的主要原因,目前尚无完全有效的治疗药物。本研究通过广泛的药物重定位,发现双环氮杂环丁烷是一类新的抗隐孢子虫化合物,在体外对三种微小隐孢子虫分离株(1%血清中EC50<0.4至96 nM)及人隐孢子虫均有抑制作用,并在部分免疫抑制小鼠模型中有效。遗传学和生化研究证实其作用机制为抑制微小隐孢子虫苯丙氨酰-tRNA合成酶(CpPheRS)。
要点
- 双环氮杂环丁烷在体外对微小隐孢子虫和人隐孢子虫均有纳摩尔级抑制活性。
- 该系列在四只高度易感免疫抑制小鼠中的三只显示治疗效果。
- 作用机制为抑制CpPheRS,耐药突变由CRISPR-Cas9编辑pheRS基因产生。
核心结论
- 双环氮杂环丁烷是有前景的抗隐孢子虫药物候选系列,并建立了基于靶点的药物发现框架。
研究设计与样本
- 本研究为药物重定位研究,体外评估三种微小隐孢子虫分离株及人隐孢子虫,并在免疫抑制小鼠模型中测试。
- 通过遗传、生化和化学研究鉴定作用靶点,并用CRISPR-Cas9基因编辑引入pheRS基因突变验证。
主要发现
- 双环氮杂环丁烷在1%血清中对三种微小隐孢子虫分离株的EC50为<0.4至96 nM。
- 对微小隐孢子虫和人隐孢子虫具有可比效力。
- 在四只高度易感免疫抑制小鼠中,三只经每日一次给药4天(感染后2周开始)有效。
- 遗传、生化和化学研究证明抑制CpPheRS是其作用机制。
- CRISPR-Cas9引入pheRS基因突变导致寄生虫对化合物高度耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cryptosporidium is a protozoan parasite and a leading cause of diarrheal disease and mortality in young children. Currently, there are no fully effective treatments available to cure infection with this diarrheal pathogen. In this study, we report a broad drug repositioning effort that led to the identification of bicyclic azetidines as a new anticryptosporidial series. Members of this series blocked growth in in vitro culture of three Cryptosporidium parvum isolates with EC50 's in 1% serum of <0.4 to 96 nM, had comparable potencies against Cryptosporidium hominis and C. parvum, and was effective in three of four highly susceptible immunosuppressed mice with once-daily dosing administered for 4 days beginning 2 weeks after infection. Comprehensive genetic, biochemical, and chemical studies demonstrated inhibition of C. parvum phenylalanyl-tRNA synthetase (CpPheRS) as the mode of action of this new lead series. Introduction of mutations directly into the C. parvum pheRS gene by CRISPR-Cas9 genome editing resulted in parasites showing high degrees of compound resistance. In vitro, bicyclic azetidines potently inhibited the aminoacylation activity of recombinant ChPheRS. Medicinal chemistry optimization led to the identification of an optimal pharmacokinetic/pharmacodynamic profile for this series. Collectively, these data demonstrate that bicyclic azetidines are a promising series for anticryptosporidial drug development and establish a broad framework to enable target-based drug discovery for this infectious disease.
引用
- Vinayak S, Jumani RS, Miller P, et al. Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci Transl Med. 2020. PMID: 32998973. doi:10.1126/scitranslmed.aba8412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。